We investigated the in vitro viscoelastic changes of progressive haemodilution with 4% albumin compared with normal saline (NS) using rotational thromboelastometry (ROTEM®, Pentapharm Co., Munich, Germany). Whole blood samples obtained from 20 healthy volunteers were diluted in vitro with 4% albumin or NS by 10%, 20% and 40%. Fibrinogen concentration and ROTEM® (EXTEM [screening test for the extrinsic haemostasis system], FIBTEM [EXTEM-based assay for the fibrin part of the clot]) variables including coagulation time, clot formation time (CFT), α-angle, maximum clot firmness and lysis index were measured in the undiluted sample and at each degree of haemodilution. There was no significant difference in fibrinogen concentration at equivalent haemodilutions with normal saline and 4% albumin solutions. Forty percent haemodilution with albumin significantly prolonged coagulation time (EXTEM P=0.007, FIBTEM P=0.0001) and significantly decreased lysis index (FIBTEM P=0.009) compared with NS. A significant decrease in maximum clot firmness from undiluted measurements (P=0.05) was observed at lower haemodilutions with albumin (20% with EXTEM, 10% with FIBTEM) compared with NS (40% with EXTEM and FIBTEM). The adverse effects of large degrees of haemodilution with 4% albumin solution are in excess of what can be explained by haemodilution alone. This study suggests that large degrees of haemodilution with albumin impair fibrinogen activity to a greater extent than equivalent degrees of haemodilution with NS.
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Key Words: thromboelastometry, fibrinogen, haemodilution, albumin, coagulation Colloid intravenous fluids are widely used for intravascular volume expansion in the resuscitation of surgical patients experiencing acute haemorrhage. There are concerns about the negative effects of colloids on coagulation, beyond that which results from haemodilution alone. Whilst there is accumulating evidence suggesting that synthetic colloids impair coagulation [1] [2] [3] [4] , the reported effects of albumin on coagulation are varied. Albumin has been demonstrated to impair in vitro clot formation and strength at haemodilutions greater than 30% 2-4 and to decrease fibrinogen concentrations in vivo 5, 6 . However, hypercoagulability at dilutions up to 50% has also been demonstrated 7-9 and impaired coagulation is only observed with severe haemodilution 10, 11 . Other studies reported that the coagulation effects of albumin are limited to haemodilution only 1 . In comparison, crystalloid solutions induce a hypercoagulable state in vitro and in vivo at lesser haemodilutions 2, [11] [12] [13] [14] [15] [16] [17] and impair coagulation only with profound haemodilution 10, [18] [19] [20] .
The aims of this study were to investigate the direct effects of albumin on coagulation and to determine whether they extend beyond haemodilution alone. We investigated the in vitro effects on coagulation of progressive haemodilution with 4% albumin (Albumex ® 4, CSL, Melbourne, Victoria) compared with equivalent dilutions with normal saline (NS) 0.9% using rotational thromboelastometry (ROTEM) (ROTEM ® , Pentapharm Co., Munich, Germany).
Methods
After approval by the Sydney Local Health District Ethics Review Committee (Protocol No. X13-0230 and HREC/13/ RPAH/294), and with written informed consent, 20 healthy volunteers (11 male, 9 female) aged between 25 and 42 years were recruited. Exclusion criteria included known coagulation disorders, other haematological disease, renal or liver disease and the use of anticoagulants or nonsteroidal anti-inflammatory drugs within seven days of blood sampling.
Blood sampling and haemodilution
The venous blood samples were obtained from an antecubital vein with minimal stasis using a 21-G needle with Vacutainer system (Becton Dickinson and Company, Franklin Lakes NJ, USA) into sample tubes containing ethylenediaminetetraacetic acid or citrate. To exclude initial coagulation activation from venepuncture and venous stasis, the ethylenediaminetetraacetic acid tube (for full blood count) was sampled first, equivalent to a 'twosyringe technique', to exclude this first 3 ml of blood from coagulation analysis.
The venous blood samples were diluted in fixed proportion by 1:9 (10%), 1:4 (20%) and 1:1.5 (40%) with either 4% albumin or 0.9% NS. The 10% haemodilution was chosen for its clinical relevance as it corresponds to a 70 kg subject with an estimated blood volume of 70 ml/kg receiving approximately 500 ml of fluid. The upper limit of 40% was selected as it equates to the administration of two litres of fluid, commonly undertaken in clinical practice prior to the commencement of blood transfusion.
Haematological measurements
The routine laboratory measurements of haemoglobin concentration, white cell count, platelet count, International Normalized Ratio and activated partial thromboplastin time were performed on each venous blood sample. On the undiluted and haemodiluted samples, fibrinogen levels were measured in duplicate by the Clauss method using STA ® Fibrinogen reagent with the STA-R analyser (Diagnostica Stago, Asnieres, France).
Rotational thromboelastometry
Coagulation tests were performed on the diluted blood samples as well as undiluted controls using ROTEM, a pointof-care test that measures the viscoelastometric properties of citrated whole blood for real-time assessment of clotting speed and strength. For the screening test for the extrinsic haemostasis system (EXTEM) assay, 300 μl of citrated blood was recalcified with 20 μl of Star-Tem ® reagent (ROTEM, Pentapharm Co., Munich, Germany) containing 0.2 mol/l of calcium chloride followed by the addition of recombinant tissue factor to trigger the extrinsic pathway (Ex-Tem ® reagent [ROTEM, Pentapharm Co., Munich, Germany]). For the EXTEM-based assay for the fibrin part of the clot (FIBTEM), 300 μl of citrated blood was mixed with 20 μl of Ex-Tem reagent, plus 20 μl of cytochalasin dimethyl sulfoxide-d 6 solution containing 0.2 mol/l calcium chloride (Fib-Tem ® reagent [ROTEM, Pentapharm Co., Munich, Germany]). Cytochalasin D acts as a platelet inhibitor and hence the FIBTEM assay measures the formation of a fibrin clot only. The FIBTEM assay, particularly FIBTEM maximum clot firmness (MCF), is found to be well correlated with fibrinogen levels as measured by the Clauss method [21] [22] [23] [24] [25] [26] [27] .
Various ROTEM parameters are used to describe clot formation kinetics, strength and lysis. The clotting time ([CT], time from commencement of analysis until the 2 mm amplitude is reached), MCF (maximum curve amplitude, equivalent to maximum clot strength) and lysis at 30 minutes ([LI30], percentage of clot remaining after 30 minutes)-were measurements on both EXTEM and FIBTEM. The clot formation time (time elapsed from 2 mm to 20 mm amplitude) and the α-angle (angle of tangent to the curve at the 2 mm point measuring rate of initial clot formation) were only measurable with EXTEM assay.
Statistical analysis
Statistical analysis was undertaken using SPPS statistics v20.0 software (IBM, Armonk, NY, USA). All data were analysed by analysis of variance with the application of post hoc Tukey test when a significant difference was detected in view of multiple comparisons. A P-value of <0.05 was considered statistically significant. Based on previous studies, ten volunteers were estimated to provide a power of 80% at a 5% significance level to detect a 20% difference in thromboelastometric variables from control samples 10, 11, 18 .
Results
The baseline haemoglobin, platelet count, International Normalized Ratio, activated partial thromboplastin time, fibrinogen concentration and thromboelastometric measurements were within normal ranges. There was a linear decrease in fibrinogen concentration with progressive haemodilution with both fluids. There was no significant difference in fibrinogen concentrations at equivalent haemodilutions with albumin compared with NS ( Figure 1) .
The CT was increasingly prolonged with progressive haemodilution with albumin but this was only significant compared with whole blood at the 40% haemodilution with both EXTEM (P=0.007) and FIBTEM (P=0.0001) assays. There was a marginal decrease in CT at 10% and 20% haemodilution with NS compared with whole blood, although this was not statistically significant. Even at the 40% haemodilution with NS, CT remained essentially unchanged compared with whole blood (EXTEM P=0.9, FIBTEM P=0.9). CT was consistently more prolonged with [29.3] ). This was statistically significant (P=0.001) ( Figure 2 ). The EXTEM clot formation time was increasingly prolonged and the EXTEM α-angle was progressively decreased with increasing haemodilution. These were statistically significant only at 40% dilution with both diluent fluids compared with the undiluted whole blood measurements (NS P=0.0001, albumin P=0.0001) (Figures 3 and 4) .
EXTEM and FIBTEM MCF were reduced with progressive haemodilution. The reduction in MCF compared with undiluted control measurements was significant at 20% haemodilution with albumin on EXTEM (whole blood 61.7 [4.4] versus albumin 20% haemodilution 50.85 [4.9] , P=0.007). At 10% haemodilution with FIBTEM, MCF was reduced by 48% compared with whole blood (whole blood 15.2 [4.3] versus albumin 10% haemodilution 7.85 [2.8] , P=0.0001) measurements. In comparison, MCF was significantly reduced only at 40% haemodilution with NS on both EXTEM (P=0.0001) and FIBTEM (P=0.0001). EXTEM and FIBTEM MCF were reduced with haemodilution with albumin compared to NS but this was not significant ( Figure 5 ).
The LI30 was unchanged with NS haemodilution as measured by both EXTEM and FIBTEM measurements. With albumin haemodilution, FIBTEM LI30 was significantly reduced at 40% dilution compared with undiluted whole blood (P=0.009) and when compared to the equivalent haemodilution with NS (NS 99.7 [1.4] , albumin 95.6 [6.4], P=0.01) ( Figure 6 ).
Discussion
This study demonstrates that large degrees of haemodilution with 4% albumin solutions impairs coagulation in vitro to a greater extent than equivalent haemodilution with NS. Forty percent haemodilution with albumin resulted in prolonged initiation of clot formation and accelerated clot breakdown, as shown by a significantly increased CT and decreased FIBTEM LI30. Further, there was a prolonged CT, prolonged clot formation time, reduced MCF and reduced α-angle with albumin at lower amounts of haemodilution compared with NS, although these were not statistically significant. These changes were observed with both the EXTEM and FIBTEM assays. If these reductions are real, they would support previous studies that have reported on haemodilution with albumin 17, 19 . The reduction in fibrinogen concentration was similar with both fluids. This suggests that the observed impairment of coagulation is not due only to dilutional coagulopathy, but another effect of albumin resulting in impaired fibrinogen function.
In contrast to the anticoagulant effects of albumin, there was evidence of accelerated initial fibrin formation with NS, as indicated by small reductions in CT at lesser haemodilutions. This is consistent with previous in vitro [10] [11] [12] 19, 20 as well as in vivo studies 13, 15, [28] [29] [30] . Evidence of hypocoagulability associated with haemodilution with NS was observed only at 40% haemodilution. This suggests that substantial haemodilution with crystalloid is required before coagulation is impaired 10, 11, 19 .
There is a paucity of evidence regarding the clinical effects of albumin on coagulation in comparison to crystalloids. In a randomised controlled trial, Shirkladze et al 31 reported that the perioperative administration of albumin to elective cardiac surgical patients resulted in greater impairment of thromboelastometric parameters compared with Ringer's lactate infusions. Albumin administration resulted in a trend towards increased chest drainage volumes and was associated with significantly higher blood transfusion requirements 31 . The use of albumin in trauma patients has been associated with increased blood transfusion when compared with crystalloid resuscitation 6 . There is evidence that the administration of albumin to patients is an independent risk factor for prolongation of activated prothrombin time 32 .
The mechanism by which albumin impairs coagulation is yet to be established. We found no significant differences in fibrinogen concentration with haemodilution with albumin or NS, in contrast to previous studies that demonstrated a decreased fibrinogen concentration associated with the use of albumin during resuscitation of trauma patients 5, 6 . Biochemical studies reported an interaction of albumin with polymerising fibrin, resulting in a narrowing of gel fibres 33 . Further, albumin-induced coagulopathy can be effectively reversed by the addition of fibrinogen concentrate 4 , providing additional evidence of underlying fibrinogen impairment. We suggest that the impairment of coagulation may be due to an interaction between albumin and fibrinogen resulting in impaired fibrinogen activity.
A major limitation of this study is the difficulty in extrapolating in vitro changes to clinical (in vivo) situations given the complexity of the coagulation system. Although the ROTEM provides an effective means of evaluating coagulation ex vivo, it does not assess the influence of intrinsic compensatory mechanisms or the interaction of blood components with the endothelium. Further, the ROTEM test is performed under static conditions and therefore, the complex interaction between the components of coagulation under various shear rates [34] [35] is not assessed. This study did not assess the amount of residual citrate or ionised calcium present at each haemodilution, which may have implications for coagulation given than albumin has been shown to bind calcium to a greater degree than NS 11 .
Conclusion
In conclusion, this study demonstrates that large degrees of haemodilution (40%) with 4% albumin solution impair coagulation to a greater extent than equivalent degrees of haemodilution with NS. This indicates that the adverse effects of albumin on coagulation in vitro cannot be explained by haemodilution alone.
